Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women.
We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49-875), with an estimated median time to return to baseline of 311days (range 108-1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative.
['Wheatley|Shaday|S|', 'Bell|Robin J|RJ|', 'Stuckey|Bronwyn G A|BG|', 'Robinson|Penelope J|PJ|', 'Davis|Susan R|SR|']
D054869:Clinical Audit D004343:Drug Implants D004958:Estradiol D015914:Estrogen Replacement Therapy D005260:Female D006801:Humans D008875:Middle Aged D017698:Postmenopause D012189:Retrospective Studies D013997:Time Factors
Oestradiol Hormone implant Menopausal hormone therapy